亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Endoscopic mucosal resection using cold snare versus hot snare in treatment for 10–19 mm non-pedunculated colorectal polyps: protocol of a non-inferiority randomised controlled study

医学 粘膜切除术 协议(科学) 外科 随机对照试验 内窥镜检查 普通外科 内科学 病理 替代医学
作者
Qingwei Jiang,Xiaxiao Yan,Duan Wang,Shengyu Zhang,Yuelun Zhang,Yunlu Feng,Aiming Yang,Dong Wu
出处
期刊:BMJ Open [BMJ]
卷期号:13 (5): e070321-e070321 被引量:1
标识
DOI:10.1136/bmjopen-2022-070321
摘要

Introduction Cold polypectomy has the advantages of simple operation, less time-consuming and fewer complications. Guidelines have recommended cold snare polypectomy (CSP) to resect small polyps sized ≤5 mm and sessile polyps sized 6–9 mm. However, evidence is scarce regarding cold resection for non-pedunculated polyps sized ≥10 mm. Cold snare endoscopic mucosal resection (CS-EMR) combining CSP and submucosal injection was designed to improve the complete resection rate and reduce adverse events. We hypothesise that CS-EMR is non-inferior to conventional hot snare endoscopic mucosal resection (HS-EMR) in the resection of 10–19 mm non-pedunculated colorectal polyps. Methods and analysis This study is a prospective, randomised, open-label, non-inferiority, single-centre trial. Outpatients scheduled to undergo a colonoscopy and present eligible polyps will be randomised to receive either CS-EMR or HS-EMR. The primary endpoint is the complete resection. Considering that HS-EMR of 10–19 mm colorectal polyps will yield a complete resection rate of at least 92% and a non-inferiority margin of −10%, a total of 232 polyps will be included (one-sided α, 2.5%; β, 20%). The analyses are intended to evaluate first non-inferiority (lower limit 95% CI greater than −10% for group difference) and then superiority (lower limit 95% CI>0%) if non-inferiority is achieved. Secondary endpoints include en-bloc resection, the occurrence of adverse events, the use of endoscopic clips, resection time and cost. Ethics and dissemination The study has been approved by the institutional review board of the Peking Union Medical College Hospital (No. K2203). All participants in the trial will provide written informed consent. The results of this trial will be published in an open-access way. Trial registration number NCT05545787 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汤姆发布了新的文献求助10
5秒前
44秒前
yhtsyy完成签到 ,获得积分10
1分钟前
兼听则明完成签到,获得积分10
1分钟前
LONG完成签到,获得积分10
1分钟前
2分钟前
欣欣发布了新的文献求助10
2分钟前
bkagyin应助虚幻妙柏采纳,获得10
2分钟前
2分钟前
欣欣发布了新的文献求助10
2分钟前
Fiteleo完成签到,获得积分10
3分钟前
3分钟前
田様应助科研通管家采纳,获得10
3分钟前
3分钟前
虚幻妙柏发布了新的文献求助10
3分钟前
Freya1528完成签到,获得积分10
3分钟前
Fiteleo发布了新的文献求助30
4分钟前
fanf完成签到,获得积分10
4分钟前
大个应助汤姆采纳,获得10
4分钟前
烟花应助耍酷平凡采纳,获得10
4分钟前
有点意思完成签到,获得积分10
5分钟前
科目三应助科研通管家采纳,获得10
5分钟前
5分钟前
耍酷平凡发布了新的文献求助10
5分钟前
情怀应助纯情的钢铁侠采纳,获得10
5分钟前
小马完成签到 ,获得积分10
6分钟前
今后应助韩明佐采纳,获得10
6分钟前
6分钟前
6分钟前
韩明佐发布了新的文献求助10
6分钟前
fouding发布了新的文献求助10
6分钟前
脑洞疼应助耍酷平凡采纳,获得10
6分钟前
领导范儿应助fouding采纳,获得10
6分钟前
深情安青应助xiw采纳,获得30
6分钟前
韩明佐完成签到 ,获得积分10
6分钟前
6分钟前
xiw完成签到,获得积分10
6分钟前
xiw发布了新的文献求助30
7分钟前
7分钟前
所所应助科研通管家采纳,获得10
7分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Cambridge History of China: Volume 4, Sui and T'ang China, 589–906 AD, Part Two 1500
Cowries - A Guide to the Gastropod Family Cypraeidae 1200
Quality by Design - An Indispensable Approach to Accelerate Biopharmaceutical Product Development 800
Signals, Systems, and Signal Processing 610
Research Methods for Applied Linguistics 500
A Social and Cultural History of the Hellenistic World 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6394576
求助须知:如何正确求助?哪些是违规求助? 8209680
关于积分的说明 17382236
捐赠科研通 5447783
什么是DOI,文献DOI怎么找? 2880021
邀请新用户注册赠送积分活动 1856498
关于科研通互助平台的介绍 1699152